Please like and comment_老虎社区_美港股上老虎

2021-06-09

Please like and comment

Biohaven CEO says drug approval is ‘monumental’ for migraine patients

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":180601698,"tweetId":"180601698","gmtCreate":1623200382814,"gmtModify":1634035912014,"author":{"id":3576284335652964,"idStr":"3576284335652964","authorId":3576284335652964,"authorIdStr":"3576284335652964","name":"Dickson8614","avatar":"https://static.tigerbbs.com/1c6a81e28879ea087b93c6234e7b7eb8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":21,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Please like and comment</p></body></html>","htmlText":"<html><head></head><body><p>Please like and comment</p></body></html>","text":"Please like and comment","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/180601698","repostId":1111279529,"repostType":4,"repost":{"id":"1111279529","kind":"news","pubTimestamp":1623200185,"share":"https://www.laohu8.com/m/news/1111279529?lang=&edition=full","pubTime":"2021-06-09 08:56","market":"us","language":"en","title":"Biohaven CEO says drug approval is ‘monumental’ for migraine patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1111279529","media":"cnbc","summary":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “cha","content":"<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven CEO says drug approval is ‘monumental’ for migraine patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven CEO says drug approval is ‘monumental’ for migraine patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-09 08:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last ...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BHVN":"Biohaven Pharmaceutical Holding Co Ltd."},"source_url":"https://www.cnbc.com/2021/06/08/biohaven-ceo-says-drug-approval-is-monumental-for-migraine-patients.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1111279529","content_text":"Biohaven CEO Vlad Coric told CNBC Tuesday a recent approval of the company’s migraine drug will “change the paradigm” of migraine prevention and treatment.The U.S. Food and Drug Administration last week approved the medicine, Nurtec ODT, for preventative treatment of migraines. That comes about a year after Nurtec was first launched to treat the symptoms of debilitating headaches, making it the first pill approved for both acute treatment and prevention, according to Coric.\"This is a monumental approval for Biohaven and patients with migraine,\" Coric said in a \"Mad Money\" interview with Jim Cramer.\"I've been practicing medicine for 25 years, and this is the first time we have a single migraine medication that can do both of these things,\" Coric said. \"This is going to change the paradigm in which migraine is treated.\"The New Haven, Connecticut-based pharmaceutical company has recruited celebrity names like actress Whoopi Goldberg andmodel Khloe Kardashianto promote the therapy.Biohaven shares closed at $95.36 apiece Tuesday, up 6.5% from where it last traded before the announcement.","news_type":1},"isVote":1,"tweetType":1,"viewCount":86,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":20,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/180601698"}